Menu
Our Head of Preclinical Development is attending this event in person to meet the antibody community.
Our CEO and COO are attending this partnering event in person to explore opportunities to collaborate in delivering new medicines to prevent and treat infectious diseases in patients.
Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.
